Table 2.
Times to remission and to intermediate reductions of plasma porphyrins in 30 patients with porphyria cutanea tarda treated by phlebotomy or low-dose hydroxychloroquine and in the 17 patients randomized to treatment.
| All patients | Randomized patients | |||||
|---|---|---|---|---|---|---|
| Phlebotomy (N=17) |
Hydroxychloroquine (N=13) |
HR [95% CI] | Phlebotomy (N=7) |
Hydroxychloroquine (N=10) |
HR [95% CI] | |
| Months | Months | |||||
| 50% reduction in Plasma Porphyrins |
2.4 (N=17) |
2.6 (N=13) |
1.4 [0.7–3.1] | 2.1 (N=7) |
2.5 (N=10) |
1.2 [0.4–3.3] |
| 75% reduction in Plasma Porphyrins |
4.8 (N=17) |
4.1 (N=11) |
1.32 [0.6–2.9] | 6 (N=7) |
4.2 (N=9) |
1.2 [0.4–3.3] |
| Normal Plasma Porphyrins |
6.9 (N=17) |
6.1 (N=13) |
2.2 [0.9–5.1] | 6.5 (N=7) |
6.7 (N=10) |
1.0 [0.4–2.9] |
| Normal Urinary Porphyrins |
6.9 (N=17) |
4 (N=11) |
0.9 [0.4–2.0] | 3.3 (N=7) |
4.1 (N=8) |
0.6 [0.2–1.7] |
Abbreviations: HR: hazard ratio; CI: confidence interval